Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Regenxbio Inc (NQ: RGNX ) 11.56 +0.40 (+3.58%) Streaming Delayed Price Updated: 4:00 PM EST, Nov 11, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Regenxbio Inc < Previous 1 2 3 4 5 Next > 12 Health Care Stocks Moving In Wednesday's Pre-Market Session November 06, 2024 Via Benzinga What 4 Analyst Ratings Have To Say About Regenxbio October 10, 2024 Via Benzinga Assessing Regenxbio: Insights From 5 Financial Analysts September 04, 2024 Via Benzinga New Research Reveals Emergence of New Variants of Coronavirus to Boost COVID-19 Therapeutics Market Growth September 04, 2024 EQNX::TICKER_START (NASDAQ:SBFM),(NASDAQ:NVAX),(NASDAQ:RGNX),(NASDAQ:BNTX),(NYSE:ABBV) EQNX::TICKER_END Via FinancialNewsMedia Exposures COVID-19 Where Regenxbio Stands With Analysts August 05, 2024 Via Benzinga Assessing Regenxbio: Insights From 4 Financial Analysts June 07, 2024 Via Benzinga Evaluating Regenxbio: Insights From 9 Financial Analysts May 15, 2024 Via Benzinga New Research Reveals Emergence of New Variants of Coronavirus to Boost COVID-19 Therapeutics Market Growth September 04, 2024 From FN Media Group LLC Via GlobeNewswire 7 Biotech Stocks to Buy for Their Game-Changing Potential August 08, 2024 Although the market may be reeling from the recent fallout, the red ink presents a viable opportunity in these biotech stocks. Via InvestorPlace Why Is Clearside Biomedical Stock Gaining Today? June 25, 2024 Clearside Biomedical pioneers suprachoroidal drug delivery for precise, effective treatment of retinal diseases. Oppenheimer rates CLSD Outperform with a $5 target, citing its innovative SCS... Via Benzinga Where Regenxbio Stands With Analysts April 12, 2024 Via Benzinga Beyond The Numbers: 4 Analysts Discuss Regenxbio Stock March 06, 2024 Via Benzinga Regenxbio: Q4 Earnings Insights February 27, 2024 Via Benzinga 7 Biotech Stocks to Buy on the Dip: June 2024 June 24, 2024 With health being a top priority over wealth generation, these biotech stocks to buy on the dip enjoy a sound framework for speculation. Via InvestorPlace FDA Approves Expanded Use For Sarepta's Rare Muscular Dystrophy Gene Therapy June 21, 2024 The FDA has approved Sarepta Therapeutics' Elevidys for treating Duchenne muscular dystrophy in patients aged 4 and older with specific DMD gene mutations. Via Benzinga Exposures Product Safety Sarepta Skyrockets After Nabbing A Broad Label For Its Duchenne Gene Therapy June 20, 2024 The agency signed off on Elevidys for a broad population of children with the muscle-wasting disease. Via Investor's Business Daily Sarepta Jumps After Pfizer's Rival Gene Therapy Flops In Phase 3 Test June 13, 2024 Sarepta is now just awaiting the FDA's decision on whether to fully approve its gene therapy, and for whom. Via Investor's Business Daily Exposures Product Safety Goldman Sachs Optimistic About Regenxbio's Gene Therapy Pipeline, Sees Over 160% Upside June 07, 2024 Goldman Sachs initiates coverage on RGNX, citing potential of gene therapy platform. Via Benzinga Earnings Scheduled For February 27, 2024 February 27, 2024 Companies Reporting Before The Bell • Gaotu Techedu (NYSE:GOTU) is expected to report quarterly loss at $0.07 per share on revenue of $100.49 million. Via Benzinga A Preview Of Regenxbio's Earnings February 26, 2024 Via Benzinga RGNX Stock Earnings: Regenxbio Misses EPS, Misses Revenue for Q1 2024 May 08, 2024 RGNX stock results show that Regenxbio missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024. Via InvestorPlace 12 Health Care Stocks Moving In Monday's After-Market Session March 25, 2024 Via Benzinga Does This 1 New Threat Make Sarepta Therapeutics Stock Worth Selling? March 13, 2024 The threat is still emerging, but it could be significant. Via The Motley Fool This Gene Therapy Player Duchenne Data Is Impressive, Analyst Upgrades REGENXBIO March 08, 2024 REGENXBIO's promising gene therapy advancements! RBC Capital Markets upgraded REGENXBIO (RGNX), citing impressive RGX-202 trial results in Duchenne patients. Via Benzinga REGENXBIO's Muscle Wasting Disorder Drug Shows Strength, Improved Motor Function, Stock Soars March 05, 2024 Latest updates on safety and efficacy in the Phase 1/2 AFFINITY DUCHENNE trial for Duchenne muscular dystrophy. Positive results, no serious adverse events. Expect pivotal dose determination by... Via Benzinga 12 Health Care Stocks Moving In Tuesday's Pre-Market Session March 05, 2024 Via Benzinga Why Zscaler Shares Are Trading Lower By 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session March 01, 2024 Shares of Zscaler, Inc. (NASDAQ: ZS) shares fell sharply during Friday’s session following second-quarter results. Via Benzinga Cooper Companies Reports Upbeat Results, Joins Dell, NetApp, Tidewater And Other Big Stocks Moving Higher On Friday March 01, 2024 U.S. stocks were higher, with the Nasdaq Composite gaining around 0.5% on Friday. Via Benzinga Topics Stocks Exposures US Equities Gene Therapy Player REGENXBIO's RGX-121 Marks Success In Trial, Yet Faces Challenges In A Crowded Market: Analyst February 12, 2024 Insights from Wedbush analysts about the clinical effectiveness of REGENXBIO's RGX-202, market potential, and challenges posed by competitors like Sarepta Therapeutics and Pfizer. Via Benzinga The One-Minute Market Report - Sunday, Feb. 11 February 11, 2024 In this brief market report, we will take a look at the various asset classes, sectors, equity categories, exchange-traded funds, and stocks that moved the market higher, as well as the market segments... Via Talk Markets < Previous 1 2 3 4 5 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
